Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad. Read more:...
Day: 16 August 2018
Lenalidomide-based maintenance therapy may be the most effective in myeloma
Continuous therapy with lenalidomide may lead to the greatest improvements in survival outcomes among patients with newly diagnosed multiple myeloma...